Introduction
Up to 85% of all strokes are of ischemic origin and mostly due to blockage of a cerebral artery by a blood clot"" After introduction of thrombolytic therapy for the treatment of acute myocardial infarction in the early 1990s, major trials for the evaluation of this new therapeutic approach to ischemic stroke were initiated. Occlusion of a brain vessel leads to a critical reduction in cerebral perfusion and, within minutes, to ischemic infarction with a central infarct core of irreversibly damaged brain tissue and a more or less large area of hypoperfused but still vital brain tissue (the ischemic penumbra), which can be salvaged by rapid restoration of blood flow')". Therefore, the underlying rationale for the introduction and application of thrombolytic agents is the lysis of an obliterating thrombus and subsequent reestablishment of cerebral blood flow by cerebrovascular recanalizationb. The delivery of thrombolytic agents locally, at or within the occluding thrombus, has the advantage of providing a higher concentration of the particular thrombolytic agent where it is needed while minimizing the concentration systemically. Hence, local intra-arterial thrombolysis has the potential for greater efficacy with regard to arterial recanalization rates and greater safety with regard to lower risk of hemorrhage. The technique involves performing a cerebral arteriogram, localizing the occluding clot, navigating a microcatheter to the site of the clot, and administering the lytic agent at or inside the clot with or without mechanical dissolution of the thrombus. Grade of vessel occlusion is usually assessed with the Thrombolysis in Myocardial Infarction (TIMI) score, where TIMI 0 is complete occulusion, TIMI 1 minimal perfusion, TIMI 2 partial flow (recanalization), and TIMI 3 complete flow (recanalization)". The agents most commonly used or which are under investigation are urokinase, t-PA (alteplase), and pro-urokinase, all of which are usually in administered at a lower dose than used in the intravenous treatment of acute ischemic stroke.
Randomized Trials of Intravenous Thrombolysis
The first anecdotal report of thrombolytic therapy for ischemic stroke dates back to the early 1960s.
Three trials in the early 1980s investigated the effect of low-dose intravenous urokinase for the therapy of acute ischemic stroke.
These trials are different from others for several reasons, such as a late timepoint of inclusion (up to 5 or 14 days after stroke onset, respectively), the exclusion of presumed cardioembolic stroke, application of low doses of urokinase given daily for a period of several days, and the lack of assessment of clinical outcome except death and intracerebral hemorrhage (ICH).
Early Randomized Trials of Intravenous
Thrombolysis for Acute Ischemic Stroke
In the early 1990s three small trials of intravenous thrombolysis with rt-PA were carried onto, two of them in Japan.
These trials, though not large enough to prove the efficacy, very well demonstrated the feasibility of early thrombolytic therapy and also suggested a reasonable degree of safety and a potential benefit. All these trials were blinded or doubleblinded, randomized, and placebo-controlled. Mori et al randomized 31 patients with acute carotid artery territory stroke to treatment with either 20 or 30 mega-international units (MIU) duteplase (equivalent to 40 or 60mg rt-PA) or placebo given intravenously for 60 minites in a time window of 6 hours after stroke onset. Baseline and postifusion angiography demonstrated complete or partial reperfusion in 50% of patients treated with 30 MIU duteplase, 44% of those treated with 20 MIU duteplase, and 17% in the control group. Patients treated with 30 MIU duteplase showed earlier and better clinical improvement than those treated with placebo, these was one parenchymal hemorrhage in each of group. Yamaguchi and colleagues randomized 98 patients into two treatment arms (20 MIU duteplase or placebo over 60 minutes) within 6 hours. According to immediate posttreatment angiography, recanalization rates were significantly better in the treatment group than in patients receiving placebo (21% versus 4% ). In the treatment group, 16% of the patients experienced a marked clinical improvement as opposed to 6% in the placebo group ; the rates of ICH, however, were similar in the two groups. The smallest randomized trial reported was that of Haley et al"', who performed a pilot study with a time window to treatment of 3 hours in preparation for the NINDS rt-PA trial. Twenty patients received 0.85mg rt-PAwithin 90 minutes, another 7 patients within 91 to 180 minutes after stroke onset. Six patients in the 90-minutes group improved by 4 or more NIH stroke scale (NIHSS) points at 24 hours compared with 1 patient in the placebo group (P<0.05). There was no difference in the 91-to 180-minutes group, and one fatal ICH occurred in the placebo group.
The Streptokinase Trials
One pilot study and three large trials investigated the efficacy of streptokinase for acute ischemic stroke. In summary, all of the trials using streptokinase for acute ischemic stroke were prematurely stopped due to a high rate of early death, mostly due to ICH, and because of a lack of benefit at outcome in a meta-analysis as well. In the streptokinase trials together there were 92 (95% CI 65 to 120) additional fatal ICH per 1,000 treated patients (OR 6.03,95% CI 3.47 to 10.47) 20'. The higher bleeding rate may be due to pharmacological properties of streptokinase other than, for instance, rt-PA, additional anticoagulation (MAST-E), a rather small fraction of patients treated whithin 3 hours, and a rather high dose of 1.5 MU, which is identical to the dose used in myocardial infarction (MI), whereas the rt-PA studies (see below) chose approximately two thirds the dose used in MI.
Other side effects of streptokinase are a decrease in systolic blood pressure of more than 20mmHg in 33%
(only 6% in the placebo group) as well as anaphylaxis in 2.2% of the patients. Therefore, intravenous administration of streptokinase, outside the setting of a clinical investigation, is dangerous and not indicated for the management of patients with ischemic stroke. inpatients not receiveing rt-PA (5.1%). The fact that blood pressure guidelines were followed in only 47.8% and that the baseline NIHSS was only documented in 40% of the patients illustrates that intravenous thrombolysis, though an effective therapy, should be performed at experienced centers only and may explain the substantially higher rate of mortality and ICH in this study compared to other investigators. Unpublished data from Canada and Germany and our own data confirm the impression that the efficacy and risk of thrombolytic therapy seen in the controlled trials can be matched or even improved in the clinical setting.
The costs associated with intravenous thrombolytic therapy will be a factor in determining the extent of its utilization. Fagan et al analyzed data from the NINDS study and the medical literature were used to estimate the health and economic outcomes associated with using tPA in acute stroke patients. A Markov model was developed to compare the costs per 1,000 patients treated with tPA compared with the costs per 1,000 untreated patients. In the NINDS rt-PA Stroke Trial, the average length of stay was significantly shorter in tPA-treated patients than in placebo-treated patients (10.9 versus 12.4 days ; P = 0.02) and more tPA patients were discharged to home than to in-patient rehabilitation or a nursing home (48 % versus 36% ; P = 0.002). The Markov model estimated an increase in hospitalization costs of $1.7 million and a decrease in rehabilitation costs of $1.4 million and nursing home costs of $4.8 million per 1,000 treated patients with a greater than 90% probability of cost savings. The estimated impact on long-term health outcomes was 564 (CI 3 to 850) quality-adjusted life-years saved over 30 years of the model perl,000 patients, which makes a net cost savings to the health care system likely. With growing experience and better training of emergency medicine personnel, internists, and neurologists throughout all stroke services, the efficacy of intravenous thrombolytic therapy with rt-PA may even improve and the time window may be routinely extended to 6 hours after symptom onset.
Early Trials of Intra-arterial Thrombolysis for Acute Ischemic Stroke
Results of several case series on local thrombolysis in the carotid artery territory have been promising, although not convincing.
For rt-PA, doses ranged between 10 and 80mg ; for urokinase, doses usually ranged up to 1.5 million units. Time from symptom onset to treatment in the smaller series has been for the most part within 6 hours, but not within 3 hours or even 4 hours of symptom onset with regard to the mean or median. The reported complete or partial recanalization rates very substantially between less than 50% and more than 90% When combining the results of these case series, complete clot lysis is reported for 67 of 174 patients (39%) . Partial clot lysis with partial recanalization is reported for 62 of the same 174 patients (36%). The combined partial or complete recanalization rate for these patients was 75
% , clearly higher than that demonstrated in the angiography-based intravenous studies (apporoximately 55%). Each of these intra-arterial case series differs from all of the others with regard to thrombolytic agent, baseline neurological deficit, angiographic anatomy, time-to-treatment, outcome, and method of neurological evaluation at follow-up. Accordingly, conclusions regarding efficacy are not possible. The most feared complication of local intraarterial therapy for stroke, as for intravenous thrombolytic therapy, is ICH. Symptomatic ICH based on the case series is estimated to be 4%, which is lower than that reported for any intravenous thrombolysis series. However, this rate is also lower than that reported in the PROACT I and II trials, in which 24-hour CT scans were performed on all patients. Other complications of intra-arterial thrombolysis include arterial intracranial embolization, subarachnoid hemorrhage, arterial perforation, secondary embolization, hemorrhagic infarction, groin hematoma, and retroperitoneal hematoma. These complications occur infrequently, certainly in less than 5% for all the series in toto. One drawback of intraarterial in contrast to intravenous thrombolysis is the considerable time delay to angiography, and from initiation of angiography to clot lysis. There are limited data (Phase I and II) data only at present to support the combined use of intravenous and intra-arterial thrombolysis with rt-PA. A protocol of the Bridging group uses 0.6mg/kg with a 10% to 20% bolus and continuous infusion up to a maximum of 60mg rt-PA"'; when angiography is started, the infusion is stopped. The rest ofthe dose up to 90 mg maximum is given intraarterially. The underlying rationale for this approach is the reduction of any delay for thrombolysis, while still having the higher recanalization rate and proven larger time window for therapy with the intra-arterial approach.
Preliminary data in a phase II trial suggest besides of a reasonable safety profile efficacy of this technique". hours from symptom onset. Recanalization was significantly associated with rpro-UK (P = 0.0085) and TIMI 3 recanalization was achieved in 5 rpro-UK patients, as opposed to none of the placebo patients. ICH occurred in 15.4% of the rpro-UK-treated patients and 7.1% of the placebo-treated patients (non-significant) ; all patients with rpro-UK and early CT signs of>33% suffered ICH. In patients who received high-dose adjuvant heparin the recanalization rate was 81.8% ; in the low-dose heparin group (dose was lowered for reasons of safety by the safety committee) it was 40% (P = 0 .0255). Mortality was lower in the rpro-UK group, albeit not significantly.
PROACT II
PROACT II, a randomized, controlled, multicenter, open-label clinical trial with blinded follow-up, aimed to determine the clinical efficacy and safety of intraarterial rproUK in patients with acute stroke of less than 6 hours' duration caused by MCA occlusion. Eligble patients had new focal neurological signs attributable to the MCA territory, allowing initiation of treatment within 6 hours after symptom onset, a minimum NIHSS score of 4 points, and exclusion of ICH on CT. Patients with these criteria underwent angiography and were randomized (2:1) to either treatment with 9 mg rpro-UK/2 hours plus the PROACT I lower dose of heparin (2,000 IU bolus, 500IU/hour continuous infusion) or heparin alone. Mechanical disruption of the clot was not permitted. After 1 hour (4.5mg rpro-UK) a control angiogram was performed and if the clot had partially or even completely dissolved, the rest of the rpro-UK dose was administered. The primary outcome was the rate of patients with a MRS of -2 at 90 days. Secondary outcomes included MCA recanalization (TIMI 2 and 3) , the frequency of symptomatic ICH, and mortality. Of 12.323 patients screened in 54 centers, only 474 (4%) underwent angiography at a median of 4.5 hours after stroke onset, 294 of which demonstrated angiographic exclusion criteria, leaving 121 rpro-UK and 59 control patients with a median baseline NIHSS of 17 points for ITT analysis. Further, 40% of rpro-UK patients and 25% of control patients had a MRS of 2 or less (absolute benefit 15%, relative benefit 58%, number needed to treat = 7 ; P = 0.04). Mortality was 25% for the rpro UK group and 27% for the control group (P = 0.8.) The recanalization rate was 66% for the r-proUK group and 18% for the control group (P<0.001) ; TIMI 3 recanalization rates were 19% and 2%, respectively (P <0.003). All other secondary outcomes were nonsignificant. Early ICH occurred in 35% versus 13% of patients (P = 0.003) ; at 10 days the rates were 68% and 57% (P = 0.23). Early symptomatic ICH occurred only in patients with NIHSS scores > 11 within 24 hours in 10.2% of r-pro UK patients and 2% of control patients (number needed to harm = 12 ; P = 0.06).
The results of PROACT II did not suffice for FDA approval. Another study of intra-arterial pro-urokinase for acute stroke within 6 hours is planned but due to funding problems still a matter of debate (PRO-ACT III).
Recommendations for Intraarterial Thrombolysis
Intra-arterial thrombolytic therapy of acute MI and M2 occlusion with 9mg/2 hours significantly improves outcome if administered within 6 hours after stroke onset. Seven patients need to be treated in order to prevent 1 patient from death or dependence. The higher rate of symptomatic ICH (10.2% in PROACT II versus 8.8% in ECASS II, 6.4% in NINDS and 7.2% in ATLANTIS) is very well explained by the far larger baseline severity of stroke in PROACT II (NIHSS of 17 in PROACT II versus 11 in ECASS II and ATLANTIS, and 14 in NINDS). According to the Cochrane meta-anal ysis6'61 , combining PROACT I and II data (34) , there is a 0.55 OR (CI 0.31-1.00) for death or disability, an OR of 2.39 (CI 0.88-6.47) for early symptomatic ICH (7 to 10 days), and an OR of 0.75 (CI 0.4-1.42) for death from all causes at followup. Although recanalization rates may be superior with intra-arterial (66%) than with intravenous (-'zf 55 %) thrombolysis and may even be increased by careful mechanical disruption of a thrombus, in addition to the lytic effect of the drug, a limited availability of centers with 24 hour a day-7 days week interventional neuroradiology service may restrict the use of this therapy. On the other hand, the clinically more severe strokes may benefit even more from an intra-arterial than an intravenous approach. Furthermore, the time to eventual recanalization may be substantially shorter with intra-arterial thrombolysis. When we compared the treatment groups, highly sig-nificant differences in both outcome quality (p = 0.017) and survival (p = 0.005) were found to depend on establishing recanalization.These data support the concept that technically successful thrombolysis of vertebrobasilar artery occlusions is associated with beneficial clinical outcome. The greatmajority of the more than 120 patients (from all studies) treated were administered intra-arterial urokinase locally ; a few patients were given rt-PA. Treatment was almost always delayed such that no patients were reported in these series as having been treated within 3 hours of symptom onset. The median time from the beginning of treatment to the time of recanalization was reported to be 120 minutes"'. For the total group the complete or partial recanalization rate apporoximates 70% ; in reality the rate probably is somewhat lower, as partial or complete recanalization is usually not achieved in 100% of patients, as reported by Zeumer et al"'. Mortality of vertebrobasilar thromboembolism is high, with overall rates of approximately 70-80%.
Successful recanalization, however, was associated with a survival rate of 55% to 75%, as opposed to 0-10% in persistent or untreated basilar artery occlusion 63,65, Two thirds of the survivors after recanalization had a favorable outcome ; all survivors in the untreated group were moderately disabled. Other authors reported an overall mortality of 75% in 13 patients, although ten of these had experienced recanalization, non-recanalization lead to death in all patients (N = 3). The authors concluded that recanalization of the vertebrobasilar system is necessary but not sufficient for effective treatment of vertebrobasilar occlusive disease"", To address the potential risks and potential benefits of intra-arterial thrombolysis for vertebral basilar artery occlusion more fully, a randomized trial ( The Australian Urokinase Stroke Trial) is planned but has not been started to date because of expected low recruitment numbers". Grond et al reported one small case series of 12 consecutive patients in whom they investigated whether early intravenous thrombolysis could also effectively be applied in acute vertebrobasilar ischemic stroke. Patients with clinically diagnosed moderate to severe vertebrobasilar ischemic stroke with clearly determined symptom onset were treated with intravenous rt-PA within 3 hours after symptom onset, following a protocol similar to that of the NINDS study. On admission, 7 patients exhibited moderate to severe brainstem symptoms without impairment of consciousness and 5 patients had impairment of consciousness, of whom 2 were comatose. Of 12 patients, 10 had a favorable outcome after 3 months, defined as full independence (Barthel index score of 100) or return to premorbid condition. One patient had a poor outcome with complete dependence due to reocclusion after primarily successful thrombolysis, and 1 patient died of se- greater than 90% sensitivity and specifity for CTA but only 30% for Doppler ultrasound. In summary, the natural disease course of vertebrobasilar occlusion has a grim prognosis. Neuroradiological intervention with intra-arterial thrombolysis to date is the only life-saving therapy that has demonstrated benefit with regard to mortality and outcome, albeit not in a randomized trial. However, sufficient data are available to justify intra-arterial thrombolytic therapy in the light of mortality and disability in these patients. The time window for thrombolysis in the posterior circulation has not been established but may be up to and even exceed 12 hours, although Fox et al.
Suggest a time window of more than 10 hours to be associated with a poor prognosis"`. Presence or absence of vertebrobasilar vessel occlusion can be safely, noninvasively, and rapidly established by CT (or MR) angiography before a neuroradiological intervention is initiated. The data for intravenous thrombolysis in vertebrobasilar obstruction are too scarce for any recommendation to be made, but warrant further study. onstrated that physicians, including general radiologists and neurologists, do not uniformly achieve a sufficient level of sensitivity for identifying CT contraindications for thrombolytic therapy. However, radiologists can be trained to recognize early infarct signs on CT and the positive effect of being trained to read CT scans of hyperacute stroke patients has recently been demonstrated in a large trial. CT angiography (CTA) can provide additional information on stenoses or occlusions in the basal arteries of the brain, as nonionic contrast material does not affect infarction volume or worsen the symptoms of cerebral ischemia. In addition to the assessment of major vessel occlusion, CTA has the potential to deliver information about the quality of the collateral circulation as contrast enhancement in arterial branches beyond the occlusion occurs in those patients. Volume CT scanners may produce images which can be used to construct functional maps of cerebral blood volume, cerebral blood flow, or time to peak enhancement , utilizing a first pass curve of a contrast bolus. In a recent study, perfusion CT was performed within 6 hours of symptom onset in 32 patients with acute stroke symptoms and showed a good correspondence in 81% of the patients with SPECT. However, at present only one slice and not images of the whole brain can be obtained.
The need for an allround diagnostic tool with which all the important pathophysiologic aspects of hyperacute stroke can be investigated is evident. Such a method must answer five decisive questions : 1 ) Where and how large is the actual area of irreversible ischemic brain damage? 2) How old is the infarction?
3) Is there tissue at risk and how much tissue is at risk? 4) Is there a vessel occlusion and where is it? 5) Is an ICH or another underlying, nonischemic disease present? Presently, the decision to initiate intravenous rt-PA treatment is based on clinical findings and CT scanning. The reported diagnostic yield of CT within 3 h after symptom onset does not adequately meet these criteria 231. With an increasing distribution and "around the clock" availability of stroke MRI, the identification of patients more suitable for thrombolytic therapy, and those who are not, may lead to an increased benefit and a reduction in complications in patients receiving thrombolytic therapy"".
Furthermore, the rather strictly defined therapeutic window may be qualified and individualized according to the findings in each individual patient.
Conclusion, Recemmendations and Future Prospects for Thrombolysis
Overall, thrombolysis with 0.9 mg/kg rt-PA for acute ischemic stroke within 6 hours leads to a clinically significant effect in favor of treated patients but is associated with an excess rate of symptomatic ICH, which does, however, not take effect on mortality. Intravenous rt-PA (0.9mg/kg ; maximum of 90 mg) is therefore the recommended treeatment within 3 hours after stroke symptom onset. Thrombolytic therapy should be peformed in centers experienced with the procedure. The benefit from the use of intravenous rt-PA for acute ischemic stroke beyond 3 hours from onset of symptoms is lower, but definitely present in selected patients. Also, the European Stroke Initiative (EUSI) recommendations state that thrombolytic therapy is the therapy of choice within 3 hours and in selected patients up to 6 hours after stroke onset. The adjunctive use (and also the optimal timepoint of use) of antithrombotic agents is still controversial and at present no recommendation can be given with regard to concomitant administration of heparin or antiplatelet agents in the setting of thrombolytic therapy. Intravenous rt-PA is not recommended when the time of onset of stroke connot be ascertained reliably ; this includes patients in whom strokes are recognized upon awakening. Intravenous administration of streptokinase for acute ischemic stroke is dangerous and not indicated. Data on the efficacy of any other intravenously administered thrombolytic drugs are not available such that a recommendation could be provided. Intra-arterial thrombolysis with recombinant pro-urokinase is safe and effective within 6 hours after stroke onset, leading to a significantly higher rate of functional independence, also in patients with more severe baseline stroke symptoms. For vertebrobasilar artery thrombosis, intra-arterial thrombolysis, although not proven in randomized trials, if successful, may dramatically reduce mortality and disability, and therefore is the therapy of choice within 6 but eventually up to 12 hours after symptom onset. The adjunctive use (and also the optimal timepoint of use) of antithrombotic agents is still controversial and at present no recommendation can be given with regard to concomitant administration of heparin or antiplatelet agents in the setting of thrombolytic therapy. Improvements in early diagnostic evaluation of patients, particularly in MRI techniques, allow a better patient selection and possibly a qualifi- 
